Pharmacological activation of Nrf2: Cardioprotective effects of statins and metformin against dyslipidemia-induced oxidative stress
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Enhancing the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway offers a novel therapeutic strategy for cardiovascular complications linked to dyslipidemia. Commonly used drugs like statins and metformin indirectly support Nrf2 activity, reducing oxidative stress and improving heart function.
Area Of Science
- Biochemistry
- Cardiology
- Pharmacology
Background
- Oxidative stress is a key factor in cardiovascular complications associated with dyslipidemia.
- The nuclear factor erythroid 2-related factor 2 (Nrf2) pathway is crucial for cellular defense against oxidative stress and cardiac protection.
- Dyslipidemia contributes to cardiovascular disease progression through cellular damage.
Purpose Of The Study
- To explore the therapeutic potential of enhancing Nrf2 activation for cardiovascular diseases linked to dyslipidemia.
- To investigate the role of statins and metformin in modulating Nrf2 activity.
- To propose a novel approach for cardiovascular protection in metabolic disorders.
Main Methods
- Review of existing literature on oxidative stress, Nrf2 pathway, and cardiovascular diseases.
- Analysis of the indirect effects of statins and metformin on Nrf2 activation.
- Examination of the relationship between oxidative stress, Nrf2, and metabolic disorder therapies.
Main Results
- Nrf2 pathway activation is a promising strategy to mitigate oxidative damage in dyslipidemia-related cardiovascular issues.
- Statins and metformin, while not direct Nrf2 activators, modulate its activity by reducing oxidative stress and enhancing mitochondrial function.
- These drugs offer a dual protective effect against cardiovascular dysfunction.
Conclusions
- Enhancing Nrf2 activation presents a novel therapeutic avenue for cardiovascular protection in patients with metabolic disorders.
- Understanding the interplay between oxidative stress, Nrf2, and common medications can improve outcomes in cardiovascular diseases.
- This review highlights a new approach to cardiovascular care for metabolic conditions.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
...
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Phase I biotransformation, or functionalization, is a crucial chemical process that converts drugs and other xenobiotics into more water-soluble forms, facilitating expulsion from the body. It involves oxidative, reductive, and hydrolytic reactions that add or unveil polar functional groups on lipophilic substrates. Key players in phase I reactions are the mixed-function oxidases. Situated in liver cell microsomes, these enzymes predominantly carry out drug metabolism. They require molecular...